NPS Pharmaceuticals to Report Third Quarter 2012 Financial Results
NPS Pharmaceuticals, Inc.Gail Brophy, 908-450-5335
NPS Pharmaceuticals, Inc. (Nasdaq: NPSP) announced today that it will issue its third quarter 2012 financial release on Friday, November 9, 2012 at approximately 8:00 a.m. ET. The press release will be followed by a conference call and webcast at 8:30 a.m. ET.
To participate in the conference call, dial (800) 299-9086 and use passcode 55167232. International callers may dial (617) 786-2903, using the same passcode. In addition, a live audio of the conference call will be available over the Internet. Interested parties can access the event through the investors’ calendar of events page on the NPS website, .
If you are unable to participate in the live call, a replay will be available at (888) 286-8010, with passcode 27933265 until midnight ET, November 23, 2012. International callers may access the replay by dialing (617) 801-6888, using the same passcode. The webcast will also be available through the NPS website for the same period.
NPS Pharmaceuticals is a biopharmaceutical company focused on bringing orphan products to patients with rare disorders and few, if any, therapeutic options. NPS is advancing two late-stage registration programs. A New Drug Application is undergoing FDA review for Gattex® (teduglutide) as a treatment for adults with short bowel syndrome (SBS) and a Biologic License Application is being prepared for Natpara® (rhPTH[1-84]) in adult hypoparathyroidism. NPS' earlier stage pipeline includes two calcilytic compounds, NPSP790 and NPSP795, with potential application in rare disorders involving increased calcium receptor activity, such as autosomal dominant hypocalcemia with hypercalciuria (ADHH). NPS complements its proprietary programs with a royalty-based portfolio of products and product candidates that includes agreements with Amgen, GlaxoSmithKline, Janssen Pharmaceuticals, Kyowa Hakko Kirin, and Nycomed, a Takeda company.